GlassScriptPhysician profile
David J Michelson
NPI 1043233737
$6,997.49
in general payments reported to CMS, 2019-2025
21 companies · $2,521 in 2025
The $2,521 reported for 2025 was more than what 81% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $177 · 2021: $101 · 2022: $3,168 · 2023: $117 · 2024: $579 · 2025: $2,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,189 · Food and Beverage: $566 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400 · Education: $61.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,189.00 |
| Food and Beverage | $565.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
| Education | $61.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,000.00 | 2022 | |
| Itf Therapeutics LLC | $1,763.51 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $623.64 | 2025 | |
| Acadia Pharmaceuticals INC | $482.00 | 2023-2025 | Daybue |
| Allergan, INC. | $217.89 | 2019-2021 | |
| Biogen, INC. | $197.83 | 2019-2025 | Spinraza |
| Sarepta Therapeutics, INC. | $160.12 | 2019-2023 | |
| Ptc Therapeutics, INC. | $128.11 | 2019 | |
| Neuropace, INC. | $119.66 | 2024 | |
| Ns Pharma, INC. | $97.53 | 2021-2022 | |
| Genentech, INC. | $69.77 | 2020-2025 | Evrysdi |
| Travere Therapeutics, INC. | $44.66 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $38.11 | 2025 | |
| Eisai INC. | $22.13 | 2019 | |
| Upsher-Smith Laboratories LLC | $19.59 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $12.94 | 2023 | Valtoco |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Michelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.